Hansa Biopharma AB Stock OTC Markets

Equities

HNSBF

SE0002148817

Biotechnology & Medical Research

Market Closed - OTC Markets 09:30:14 2024-03-14 am EDT 5-day change 1st Jan Change
2.93 USD -9.98% Intraday chart for Hansa Biopharma AB -.--% +29.82%
Sales 2024 * 239M 22.12M Sales 2025 * 343M 31.68M Capitalization 1.64B 151M
Net income 2024 * -735M -67.96M Net income 2025 * -712M -65.84M EV / Sales 2024 * 8.82 x
Net Debt 2024 * 474M 43.83M Net Debt 2025 * 733M 67.81M EV / Sales 2025 * 6.92 x
P/E ratio 2024 *
-2.58 x
P/E ratio 2025 *
-3.06 x
Employees 166
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.98%
3 months-11.21%
6 months-2.33%
Current year+29.82%
More quotes
Current year
2.65
Extreme 2.65
3.30
1 year
2.26
Extreme 2.257
5.30
3 years
2.26
Extreme 2.257
18.20
5 years
2.26
Extreme 2.257
29.50
10 years
2.26
Extreme 2.257
35.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 18-03-19
Chief Tech/Sci/R&D Officer 53 Nov. 30
Chief Tech/Sci/R&D Officer 66 20-05-28
Members of the board TitleAgeSince
Director/Board Member 73 18-05-28
Chairman 61 22-06-29
Director/Board Member 59 19-05-21
More insiders
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.74 SEK
Average target price
105 SEK
Spread / Average Target
+253.06%
Consensus